phrykt

INSMED (INSM) debt: $547M

INSMED had $547M of long-term debt on Dec 31, 2025, including the part due within a year, down 51.3% from $1.1B a year earlier.

From INSMED's filings with the SEC · Read the filing · INSM stock page

INSMED debt by year

$800M2021$1.2B2022$1.2B2023$1.1B2024$547M2025

#1,091 of 2,129 US companies by debt · See the full ranking

Year endedDebtChange
Dec 31, 2025$547M-51%
Dec 31, 2024$1.1B-5%
Dec 31, 2023$1.2B+2%
Dec 31, 2022$1.2B+44%
Dec 31, 2021$800M–

Debt of similar companies

Companies in the same industry as INSMED, by SEC industry code, with the closest debt. Each name opens the same page for that company.

CompanyDebt, latest yearYear ended
BeOne Medicines$836MDec 31, 2025
Sarepta Therapeutics$829MDec 31, 2025
Phibro Animal Health$624MDec 31, 2025
Amphastar Pharmaceuticals$620MDec 31, 2025
Biomarin Pharmaceutical$597MDec 31, 2025
INSMED$547MDec 31, 2025
Pacira BioSciences$372MDec 31, 2025

Questions and answers

What is INSMED's debt?

INSMED had $547M of long-term debt on Dec 31, 2025, including the part due within a year, down 51.3% from $1.1B a year earlier.

Numbers as reported in INSMED's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology